CD33 and Alzheimer disease: Beyond the recognized AD genes identified in the gene lists garnered from the GWAS and single-cell RNA-seq studies, several other genes (TREM2, CD33, CHRNA2, PRSS8, ACE, TKT, APP, and GABRA1) were found to be the targets of clinical AD drugs reported by Cummings et al. (2019).